Vertex beat third-quarter expectations late Monday, but an analyst says Vertex stock needs more "to drive another leg of stock upside." ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

Sales of Vertex's top-selling CF drug Trikafta rose more than 13% to $2.59 billion for the quarter ended Sept. 30, beating analysts' estimate of $2.33 billion. The company also beat third-quarter ...